J B Hunt Transport Services Inc vs Twist Bioscience Corp — how do they compare? J B Hunt Transport Services Inc trades at $229 (market cap $21.45B), while Twist Bioscience Corp trades at $154.5 (market cap $10.08B). The key difference: J B Hunt Transport Services Inc is far larger — about 2.1× Twist Bioscience Corp's market cap, and J B Hunt Transport Services Inc pays a 0.79% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold J B Hunt Transport Services Inc for 45 Days and Twist Bioscience Corp for 27 Days on average.
| JBHT | TWST | |
|---|---|---|
Market Cap | $21.45B | $10.08B |
Volume | 1,028,680 | 4,229,037 |
Sector | Industrials | Health |
52-Week High | $298.41 | $205.00 |
52-Week Low | $137.09 | $25.45 |
Typical Hold Time | 45 Days | 27 Days |
Enterprise Value | $22.59B | $10.01B |
Dividend Yield | 0.79% | — |
Signals from Pluang's Aura AI — not financial advice
JBHT trades at $222.64, down 1.46% on the day, amid a bearish technical signal and ongoing securities class action investigations. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected October 15, 2026. Fundamentals show a P/E of 31.67, net income margin of 5.31%, and strong cash flow from operations of $1.68 billion in 2025. Analyst consensus remains bullish with a $289.40 price target, though rising costs and legal scrutiny present headwinds.
The outlook is mixed; strong freight demand and earnings beats support upside potential, but near-term pressure from fuel costs and legal overhangs may limit gains. The stock offers value if operational efficiency improves, yet investors face risks from volatile diesel prices and potential litigation outcomes. The upcoming Q3 earnings will be critical for confirming the company's ability to navigate cost pressures.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →